Open AccessImmune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study
Author(s) -
Giammaria Fiorentini,
Donatella Sarti,
Alberto Patriti,
Emilio Eugeni,
Francesco Guerra,
Francesco Masedu,
Andrew R. Mackay,
Stefano Guadagni
Publication year - 2020
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v11.i6.397
Subject(s) - medicine , cd8 , cd3 , hyperthermic intraperitoneal chemotherapy , immune system , cytotoxic t cell , immunology , lymphocyte , cd19 , cytoreductive surgery , cancer , biology , biochemistry , ovarian cancer , in vitro
Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases (PM) is considered to be feasible, safe and to improve survival.